Cargando…
SPOTlight on GLOW
The GLOW randomized double-blind phase 3 trial(1) shows that Claudin-18.2 targeting antibody zolbetuximab combined with capecitabine and oxaliplatin improves outcome compared to placebo and chemotherapy as first-line treatment in Claudin-18.2-positive, HER2-negative gastric or gastroesophageal junct...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591046/ https://www.ncbi.nlm.nih.gov/pubmed/37852180 http://dx.doi.org/10.1016/j.xcrm.2023.101233 |